abstract |
The present invention relates to an antibody having a binding specificity for IL-6 and a fragment thereof for the prevention or treatment of cachexia, fever, frailty, and / or fatigue in a patient in need thereof. Intended for the treatment method used. In preferred embodiments, the anti-IL-6 antibody is humanized and / or deglycosylated. In a preferred embodiment, these patients also include patients who show elevated (or at risk of developing) serum C-reactive protein levels prior to treatment. In another preferred embodiment, the patient's survival rate or quality of life is preferably improved. [Selection figure] None |